| Literature DB >> 26374897 |
Charles C Bailey1, Lindsey B DeVaux2, Michael Farzan2.
Abstract
The triggering receptor expressed on myeloid cells 2 (TREM2) is an Ig-like V-type receptor expressed by populations of myeloid cells in the central nervous system and periphery. Loss-of-function mutations in TREM2 cause a progressive, fatal neurodegenerative disorder called Nasu-Hakola disease. In addition, a TREM2 R47H coding variant was recently identified as a risk factor for late-onset Alzheimer disease. TREM2 binds various polyanionic molecules but no specific protein ligands have been identified. Here we show that TREM2 specifically binds apolipoprotein E, a well established participant in Alzheimer disease. TREM2-Ig fusions efficiently precipitate ApoE from cerebrospinal fluid and serum. TREM2 also binds recombinant ApoE in solution and immobilized ApoE as detected by ELISA. Furthermore, the Alzheimer disease-associated R47H mutation, and other artificial mutations introduced in the same location, markedly reduced the affinity of TREM2 for ApoE. These findings reveal a link between two Alzheimer disease risk factors and may provide important clues to the pathogenesis of Nasu-Hakola disease and other neurodegenerative disorders.Entities:
Keywords: Alzheimer disease; Nasu-Hakola disease; PLOSL; TREM2; apolipoprotein E (ApoE); genetic polymorphism; high-density lipoprotein (HDL); myeloid cell; neurodegenerative disease
Mesh:
Substances:
Year: 2015 PMID: 26374897 PMCID: PMC4646256 DOI: 10.1074/jbc.M115.677286
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157